New Advane of Reaserch on Relationship between Long Noncoding RNA and Acute Myeloid Leukemia--Review.
10.19746/j.cnki.issn.1009-2137.2020.04.057
- Author:
Zhang FANG
1
;
Zhe YANG
1
;
Ming-Ming ZHU
1
;
Duo-Nan YU
2
Author Information
1. Jiangsu Provineial Key Laboratory of Experimental & Translational Noncoding RNA Research, Yangzhou University School of Medicine, Yangzhou 225009, Jiangsu Province, China.
2. Jiangsu Provineial Key Laboratory of Experimental & Translational Noncoding RNA Research, Yangzhou University School of Medicine, Yangzhou 225009, Jiangsu Province, China. E-mail: dnyu@yzu.edu.cn.
- Publication Type:Journal Article
- MeSH:
Genes, Regulator;
Humans;
Leukemia, Myeloid, Acute;
genetics;
Prognosis;
RNA, Long Noncoding
- From:
Journal of Experimental Hematology
2020;28(4):1414-1418
- CountryChina
- Language:Chinese
-
Abstract:
Acute myeloid leukemia（AML）is a myelopoietic stem/progenitor malignant disease. The exact etiology of this leukemia remains unclear, thus it is important to explore the pathogenesis of AML and to discover the new diagnostic markers and therapeutic targets. The long non coding RNA (lnc RNA) is a class of RNA molecules with transcripts over 200 nucleotides in eukaryotic cells which almost don't possess the ability to code proteins, but can regulate the expression of other genes at transcriptional and post-transcriptional levels, thereby participate in occurrence and development of varied tumors. Of late years, along with the deepening of study, the lncRNA roles played in the AML have been reported and confirmed. In this review, the relationships between the IncRNA (UCA1, ANRIL, H19, HOTAIR, CCAT1, ZFAS1, LINC00152, HOXA-A52, NEAT1, TUG1, IRAIN1, PANDAR, LINC00899, SNHG5, and KCNQ1OT1) and AML is summarized briefly, so as to provide the potential basis for the clinical diagnosis and therapy of AML.
